Published in Vaccine Weekly, April 30th, 2003
"The data show that our anthrax drug works in animals to protect them from the harmful effects of anthrax toxin," said Stephen Sudovar, president and CEO of Elusys. "These trials also demonstrate that the heteropolymer technology can take antibodies that may be harmful on their own and make them beneficial."
Elusys is developing a heteropolymer (HP) to remove anthrax toxin from the bloodstream. The toxin is the component of anthrax that can seriously harm and kill people. Currently there are few useful...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly